WO1993012814A3 - Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations - Google Patents
Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations Download PDFInfo
- Publication number
- WO1993012814A3 WO1993012814A3 PCT/US1992/011159 US9211159W WO9312814A3 WO 1993012814 A3 WO1993012814 A3 WO 1993012814A3 US 9211159 W US9211159 W US 9211159W WO 9312814 A3 WO9312814 A3 WO 9312814A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- pathology
- tcr
- vaccine
- vaccines
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000001717 pathogenic effect Effects 0.000 title abstract 2
- 238000002255 vaccination Methods 0.000 title 1
- 108091008874 T cell receptors Proteins 0.000 abstract 6
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 6
- 229960005486 vaccine Drugs 0.000 abstract 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 5
- 230000007170 pathology Effects 0.000 abstract 4
- 201000006417 multiple sclerosis Diseases 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 230000008506 pathogenesis Effects 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 231100000617 superantigen Toxicity 0.000 abstract 1
- 230000009258 tissue cross reactivity Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides vaccines and a means of vaccinating a vertebrate so as to prevent or control specific T cell mediated pathologies, including autoimmune diseases and the unregulated replication of T cells. The vaccine is composed of a T cell receptor (TCR) or a fragment thereof corresponding to a TCR present on the surface of T cells mediating the pathology. The vaccine fragment can be a peptide corresponding to sequences of TCRs characteristic of the T cells mediating said pathology. Such a peptide can bind to conventional antigens complexed to MHC antigen presenting cells or to superantigens. Means of determining appropriate amino acid sequences for such vaccines are also provided. The vaccine is administered to the vertebrate in a manner that induces an immune response directed against the TCR of T cells mediating the pathology. This immune response down regulates or deletes the pathogenic T cells, thus ablating the disease pathogenesis. The invention additionally provides specific β-chain variable regions of T cell receptors, designated Vβ3, Vβ4, Vβ12, Vβ14 and V, β17, which are associated with the pathogenesis of autoimmune diseases, such as rheumatoid arthritis (RA) and multiple sclerosis (MS). Also provided are means to detect, prevent and treat RA and MS. Methods of administering DNA or RNA encoding the polypeptides useful as vaccines of the present invention into the tissue cells of an individual is also provided.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5511865A JPH07506563A (en) | 1991-12-24 | 1992-12-21 | Vaccination and methods for diseases caused by pathogenic responses by specific T cell populations |
| EP93902714A EP0623025A1 (en) | 1991-12-24 | 1992-12-21 | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81386791A | 1991-12-24 | 1991-12-24 | |
| US813,867 | 1991-12-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1993012814A2 WO1993012814A2 (en) | 1993-07-08 |
| WO1993012814A3 true WO1993012814A3 (en) | 1993-09-30 |
Family
ID=25213619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1992/011159 WO1993012814A2 (en) | 1991-12-24 | 1992-12-21 | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0623025A1 (en) |
| JP (1) | JPH07506563A (en) |
| AU (1) | AU3418893A (en) |
| CA (1) | CA2126686A1 (en) |
| WO (1) | WO1993012814A2 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5667967A (en) * | 1990-05-01 | 1997-09-16 | The Board Of Trustees Of The Leland Stanford Junior University | T-cell receptor varible transcripts as disease related markers |
| US6413516B1 (en) * | 1989-03-21 | 2002-07-02 | The Immune Response Corporation | Peptides and methods against psoriasis |
| US6464978B1 (en) * | 1989-03-21 | 2002-10-15 | The Immune Response Corporation | Vaccination and methods against multiple sclerosis resulting from pathogenic responses by specific T cell populations |
| US5776459A (en) * | 1989-07-19 | 1998-07-07 | Connetics Corporation | TCR V beta 5 peptides |
| WO1993025680A1 (en) * | 1992-06-08 | 1993-12-23 | Colorado State University Research Foundation | ENDOGENOUS LIGANDS FOR CDR4 OF T-CELL RECEPTOR β-CHAINS AND GENES ENCODING THE SAME |
| CA2172512A1 (en) * | 1993-09-22 | 1995-03-30 | Lawrence Steinman | Interaction of t-cell receptors and antigen in autoimmune disease |
| US6379670B1 (en) | 1994-11-18 | 2002-04-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
| US6251396B1 (en) | 1994-11-18 | 2001-06-26 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
| WO1996021028A2 (en) * | 1995-01-03 | 1996-07-11 | Procept, Inc. | Soluble heterodimeric t cell receptors and their antibodies |
| LT4475B (en) * | 1997-02-28 | 1999-02-25 | Virmantas Stunžėnas | Use of the i-rna in the pharmaceuticals for increasing of the amount of protein encoded by said rna in patient cells |
| WO1999027957A1 (en) * | 1997-12-03 | 1999-06-10 | The Immune Response Corporation | Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides |
| WO2000014116A1 (en) * | 1998-09-04 | 2000-03-16 | Baylor College Of Medicine | T cell peptides as therapeutics for immune-related disease |
| HUP0202574A2 (en) | 1999-02-23 | 2002-12-28 | Baylor College Medicine | T cell receptor vbetha-dbetha-jbetha sequence and methods for its detection |
| US6541608B1 (en) | 1999-02-23 | 2003-04-01 | Baylor College Of Medicine | T cell receptor Vβ-Dβ-Jβ sequence and methods for its detection |
| DE102007001370A1 (en) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-encoded antibodies |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990011294A1 (en) * | 1989-03-21 | 1990-10-04 | The Immune Response Corporation | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
| WO1991001133A1 (en) * | 1989-07-19 | 1991-02-07 | Arthur Allen Vandenbark | T cell receptor peptides as therapeutics for autoimmune and malignant disease |
| WO1991015225A1 (en) * | 1990-03-30 | 1991-10-17 | Brigham And Women's Hospital | Multiple sclerosis t-cell receptor |
| WO1992012996A2 (en) * | 1991-01-22 | 1992-08-06 | The Immune Response Corporation | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
-
1992
- 1992-12-21 JP JP5511865A patent/JPH07506563A/en active Pending
- 1992-12-21 WO PCT/US1992/011159 patent/WO1993012814A2/en not_active Application Discontinuation
- 1992-12-21 CA CA002126686A patent/CA2126686A1/en not_active Abandoned
- 1992-12-21 AU AU34188/93A patent/AU3418893A/en not_active Abandoned
- 1992-12-21 EP EP93902714A patent/EP0623025A1/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990011294A1 (en) * | 1989-03-21 | 1990-10-04 | The Immune Response Corporation | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
| WO1991001133A1 (en) * | 1989-07-19 | 1991-02-07 | Arthur Allen Vandenbark | T cell receptor peptides as therapeutics for autoimmune and malignant disease |
| WO1991015225A1 (en) * | 1990-03-30 | 1991-10-17 | Brigham And Women's Hospital | Multiple sclerosis t-cell receptor |
| WO1992012996A2 (en) * | 1991-01-22 | 1992-08-06 | The Immune Response Corporation | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
Non-Patent Citations (1)
| Title |
|---|
| CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY vol. 62, no. 1(1), January 1992, NEW YORK, US pages 1 - 7 S. BROSTOFF ET AL. 'T cell receptors, immunoregulation, and autoimmunity.' * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1993012814A2 (en) | 1993-07-08 |
| JPH07506563A (en) | 1995-07-20 |
| AU3418893A (en) | 1993-07-28 |
| CA2126686A1 (en) | 1993-07-08 |
| EP0623025A1 (en) | 1994-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1992012996A3 (en) | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations | |
| WO1993012814A3 (en) | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations | |
| Willenborg et al. | IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. | |
| Ober et al. | Vaccine-induced, pseudorabies virus-specific, extrathymic CD4+ CD8+ memory T-helper cells in swine | |
| Janeway | Immunogenecity signals 1, 2, 3... and 0 | |
| Ohkusu et al. | Potentiality of interleukin-18 as a useful reagent for treatment and prevention of Leishmania major infection | |
| Matis et al. | Major histocompatibility complex-linked specificity of γδ receptor-bearing T lymphocytes | |
| Sedegah et al. | Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine | |
| Thomas et al. | CD8 T cells inhibit IgE via dendritic cell IL-12 induction that promotes Th1 T cell counter-regulation | |
| RU2136697C1 (en) | Method of oligopeptide producing | |
| Baggi et al. | Breakdown of tolerance to a self-peptide of acetylcholine receptor α-subunit induces experimental myasthenia gravis in rats | |
| Iwakura et al. | Autoimmunity induction by human T cell leukemia virus type 1 in transgenic mice that develop chronic inflammatory arthropathy resembling rheumatoid arthritis in humans. | |
| ES2062519T5 (en) | VACCINATION AND METHODS AGAINST DISEASES ORIGINATED FROM PATHOGENIC RESPONSES THROUGH SPECIFIC POPULATIONS OF LYMPHOCYTES T. | |
| Murray et al. | Functional CD4 T cell subset interplay in an intact immune system | |
| Von Boehmer | CD4/CD8 lineage commitment: back to instruction? | |
| Matsumoto et al. | Inability of IL-12 to down-regulate IgE synthesis due to defective production of IFN-γ in atopic NC/Nga mice | |
| CHUN et al. | Constitutive and regulated expression of the class Ib molecule Qa‐1 in pancreatic β cells | |
| Pardoll et al. | The unfolding story of T cell receptor γ | |
| Pye et al. | Failure of recombinant vaccinia viruses expressing Plasmodium falciparum antigens to protect Saimiri monkeys against malaria | |
| Morgan et al. | Vaccination with a CDR2 BV6S2/6S5 peptide in adjuvant induces peptide‐specific T‐cell responses in patients with multiple sclerosis | |
| JP2000515016A (en) | High affinity interleukin-4 mutein | |
| Wang et al. | Enhancement of EAE and induction of autoantibodies to T-cell epitopes in mice infected with a recombinant vaccinia virus encoding myelin proteolipid protein | |
| Kretz-Rommel et al. | Persistence of autoreactive T cell drive is required to elicit anti-chromatin antibodies in a murine model of drug-induced lupus | |
| Nicholas et al. | A 16-amino acid peptide of respiratory syncytial virus 1A protein contains two overlapping T cell-stimulating sites distinguishable by class II MHC restriction elements. | |
| Offner et al. | Vaccination with BV8S2 protein amplifies TCR-specific regulation and protection against experimental autoimmune encephalomyelitis in TCR BV8S2 transgenic mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NZ PL RO RU SD |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NZ PL RO RU SD |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2126686 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1993902714 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1993902714 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1993902714 Country of ref document: EP |